Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Purpose Imatinib mesylate is a targeted agent that may be used against Philadelphia
chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk …

Background The combination of chemotherapy and ponatinib in Philadelphia chromosome-
positive acute lymphoblastic leukaemia has the potential to be a new standard of care for the …

Background Trials of imatinib have provided evidence of activity in adults with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given …

Assessment of minimal residual disease (MRD) has acquired a prominent position in
European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the …

The combination of cytotoxic chemotherapy and imatinib has improved the outcome for
patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) …

Purpose Minimal residual disease (MRD) before allogeneic stem-cell transplantation was
shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in …

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four
consecutive risk-adapted trials by the PETHEMA Study Group - PMC Back to Top Skip to main …

Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+
acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration …

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly
heterogeneous disease comprising many entities for which distinct treatment strategies are …